317 related articles for article (PubMed ID: 19667989)
21. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
[TBL] [Abstract][Full Text] [Related]
24. Targeting alloantibody production with bortezomib: does it make more sense?
Lee I; Constantinescu S; Gillespie A; Rao S; Silva P; Birkenbach M; Leech S; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2010; ():397-403. PubMed ID: 21696057
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
[No Abstract] [Full Text] [Related]
26. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
Lubetzky M; Auli MJ; Walker J; Leeser D; Kapur S; Hartono C; Dadhania D
Clin Transpl; 2010; ():437-40. PubMed ID: 21696061
[No Abstract] [Full Text] [Related]
27. Bortezomib is effective to treat acute humoral rejection after liver transplantation.
Lee CF; Eldeen FZ; Chan KM; Wu TH; Soong RS; Wu TJ; Chou HS; Lee WC
Transplant Proc; 2012 Mar; 44(2):529-31. PubMed ID: 22410063
[TBL] [Abstract][Full Text] [Related]
28. Protective immunity remains intact after antibody removal by means of proteasome inhibition.
Everly MJ; Terasaki PI; Hopfield J; Trivedi HL; Kaneku H
Transplantation; 2010 Dec; 90(12):1493-8. PubMed ID: 21042236
[TBL] [Abstract][Full Text] [Related]
29. Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.
Gheith O; Al-Otaibi T; Nampoory N; Halim M; Nair P; Saied T; Al-Waheeb S; Muzeirei I; Ibraheim M
Exp Clin Transplant; 2012 Aug; 10(4):406-9. PubMed ID: 22746156
[TBL] [Abstract][Full Text] [Related]
30. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.
Walsh RC; Brailey P; Girnita A; Alloway RR; Shields AR; Wall GE; Sadaka BH; Cardi M; Tevar A; Govil A; Mogilishetty G; Roy-Chaudhury P; Woodle ES
Transplantation; 2011 Jun; 91(11):1218-26. PubMed ID: 21617586
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
Island ER; Gonzalez-Pinto IM; Tsai HL; Ruiz P; Tryphonopoulos P; Gonzalez ML; Solano JP; Rossique M; Selvaggi G; Tekin A; Smith LJ; Tzakis AG
Clin Transpl; 2009; ():465-9. PubMed ID: 20524316
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition for antibody-mediated allograft rejection.
Sadaka B; Alloway RR; Shields AR; Schmidt NM; Woodle ES
Semin Hematol; 2012 Jul; 49(3):263-9. PubMed ID: 22726550
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.
Sberro-Soussan R; Zuberl J; Suberbielle-Boissel C; Legendre C
Clin Transpl; 2010; ():409-14. PubMed ID: 21696059
[TBL] [Abstract][Full Text] [Related]
34. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib rescue in refractory acute humoral rejection--report of a case.
Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
[No Abstract] [Full Text] [Related]
36. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
37. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Mitsiades CS
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
[TBL] [Abstract][Full Text] [Related]
38. Clinical and investigational use of proteasome inhibitors for transplant rejection.
Sadaka B; Alloway RR; Woodle ES
Expert Opin Investig Drugs; 2011 Nov; 20(11):1535-42. PubMed ID: 21916809
[TBL] [Abstract][Full Text] [Related]
39. 1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.
Shapiro R; Lunz J; Zeevi A; Basu A; Mapara M; Randhawa P; Tan HP; Sharma V; Humar A
Clin Transpl; 2010; ():405-7. PubMed ID: 21696058
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitor-based therapy for antibody-mediated rejection.
Walsh RC; Alloway RR; Girnita AL; Woodle ES
Kidney Int; 2012 Jun; 81(11):1067-74. PubMed ID: 22336990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
